An independent board gave Novocure (NVCR) the go-ahead on Tuesday to recruit fewer patients for a study in lung-cancer treatment. The news sent NVCR stock rocketing.
After reviewing interim data, the Data and Safety Monitoring Board accelerated Novocure's late-stage study in non-small cell lung cancer. It stated Novocure doesn't need to reach 534 patients with 18 months of follow-up. Instead, it recommended the company test 276 patients with 12 months of follow-up time.
The news bodes well for Novocure's technology, tumor-treating fields. The body-worn device uses electrical fields to interrupt cell division. By doing so, it aims to prevent the process in which cancer spreads.
Novocure's study pits tumor-treating fields and cancer drugs known as checkpoint inhibitors against a regime of checkpoint inhibitors and chemotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.